Our Grants

CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.

See our complete portfolio of awards below.

View Funded Institutions
View Funded Investigators
Find Clinical Trials

All CIRM Grants

Search Filters »

Institution Researcher name Grant Type Grant Title Award Value
University of California, San Diego Shu Chien Tools and Technologies II Development of Synthetic Microenvironments for Stem Cell Growth and Differentiation $1,706,628
University of California, Los Angeles Dr. Thomas Carmichael M.D., Ph.D. Tools and Technologies II Development of a Hydrogel Matrix for Stem Cell Growth and Neural Repair after Stroke $1,825,613
Stanford University Dr. Michele Calos Tools and Technologies II Site-specific integration of Lmx1a, FoxA2, & Otx2 to optimize dopaminergic differentiation $1,592,897
Fluidigm Corporation Dr. Marc A Unger Tools and Technologies II Development and Application of Versatile, Automated, Microfluidic Cell Culture System $1,939,236
University of California, Los Angeles Dr. Martin Gabriel Martin Tools and Technologies II Pluripotent and Somatic Stem Cell Models to Study Inherited Diarrheal Disorders $1,783,250
University of California, Los Angeles Dr. Sophie X Deng Early Translational II Regeneration of Functional Human Corneal Epithelial Progenitor Cells $697,507
University of California, San Francisco Dr. Arturo Alvarez-Buylla Early Translational II Inhibitory Nerve Cell Precursors: Dosing, Safety and Efficacy $1,564,016
University of California, Davis Dr. Mark Zern Early Translational II Liver Cell Transplantation $4,212,621
Stanford University Dr. Michele Calos Early Translational II Stem Cell Therapy for Duchenne Muscular Dystrophy $2,267,261
University of California, Irvine Dr. Brian J. Cummings Early Translational II Neural restricted, FAC-sorted, human neural stem cells to treat traumatic brain injury $1,517,767
University of California, Los Angeles Dr. Sophie X Deng Early Translational II Regeneration of Functional Human Corneal Epithelial Progenitor Cells $1,524,947
Cedars-Sinai Medical Center Dr. Dan Gazit Early Translational II Systemic Adult Stem Cell Therapy for Osteoporosis-Related Vertebral Compression Fractures $1,927,698
University of California, Los Angeles Leif Havton Early Translational II Repair of Conus Medullaris/Cauda Equina Injury using Human ES Cell-Derived Motor Neurons $75,628
University of California, Irvine Leif A Havton Early Translational II Repair of Conus Medullaris/Cauda Equina Injury using Human ES Cell-Derived Motor Neurons $1,527,011
City of Hope, Beckman Research Institute Dr. Yanhong Shi Early Translational II Developing a therapeutic candidate for Canavan disease using induced pluripotent stem cell $1,835,983
Stanford University Dr. Katja Weinacht Preclinical Stage Projects Therapeutic Restoration of Immune Function through iPSC-derived Human Thymic Epithelial Cells $12,999,871
EVADE Therapeutics Sonja Schrepfer Preclinical Stage Projects Hypoimmune Stem Cell–Derived Islets: A Next-Generation Cell Therapy Toward a Functional Cure for Type 1 Diabetes $12,480,000
University of Southern California Charles Murry Preclinical Stage Projects Regenerating the Acutely Infarcted Heart with iPSC-Ventricular Cardiomyocytes. $7,499,998
University of California, Los Angeles Dr. Lili Yang Preclinical Stage Projects Stem Cell-Engineered Off-The-Shelf CAR-NKT Cell Therapy for Multiple Sclerosis $7,499,996
Scribe Therapeutics Brett Staahl Preclinical Stage Projects A First-in-Class CIRSPR-CasX Gene Editing Therapy for Lowering Lp(a) to Prevent Cardiovascular Events $12,714,480
4D Molecular Therapeutics, Inc. Sara Collins Preclinical Stage Projects Gene Therapy for Alpha-1 Anti-Trypsin Deficiency $5,915,073
AcuraStem Incorporated Mr. Samuel V. Alworth MS, MBA Preclinical Stage Projects Late-stage development of AS-241, an UNC13A Targeting Antisense Oligonucleotide treatment for Amyotrophic Lateral Sclerosis, for IND-enabling studies $7,500,000
Cure Rare Disease Dr. Tahseen Mozaffar Preclinical Stage Projects Advancement of a myotropic, liver-detargeting therapy for LGMD2i/R9 $7,292,297
Scribe Therapeutics Brett Staahl Preclinical Stage Projects A first-in-class CRISPR-CasX gene editor silencing APOC3 transcription for the treatment of Severe Hypertriglyceridemia $13,000,000
Savanna Biotherapeutics, Inc. Dr. Sunil Gandhi Ph.D Preclinical Stage Projects Microglia replacement therapy for CSF1R-related Leukoencephalopathy $12,993,456
Cedars-Sinai Medical Center Dr. David Joseph Lefer Preclinical Stage Projects TY1 and Semaglutide to Treat Cardiometabolic HFpEF $10,571,220
University of California, San Diego Dr. Stephanie Cherqui Preclinical Stage Projects CRISPR/Cas9-mediated gene editing of Hematopoietic stem and progenitor cells for Friedreich’s ataxia $7,423,504
Cedars-Sinai Medical Center Dr. Alessandra Ciullo Preclinical Stage Projects Noncoding RNA drug TY2 for arrhythmogenic cardiomyopathy $10,419,929
Navega Therapeutics Ana Maria Moreno Preclinical Stage Projects Development of an AAV Epigenetic Gene Therapy for Intractable Chronic Pain Disorders $9,486,864
Scripps Health Dr. Darryl D. D’Lima Preclinical Stage Projects Stem Cell-Based Cartilage Tissue Regeneration $12,715,000
Stanford University Dr. Bertha Chen Preclinical Stage Projects Autologous iPSC-derived progenitor smooth muscle cells for treatment of urinary incontinence $7,275,596
Loma Linda University Hisham Abdel-Azim CCCE Grant Inland Empire and Desert Region CIRM Community Care Center of Excellence $9,000,000
Fresno Community Hospital and Medical Center Haifaa Abdulhaq CCCE Grant Establishing a CIRM Community Care Center of Excellence in the Central Valley $8,996,101
Lundquist Institute for Biomedical Innovation at Harbor – UCLA Medical Center Lynda Polgreen MD CCCE Grant South Los Angeles Community Center of Excellence for Regenerative Medicine $9,000,000
Stanford University Dr. Michael P Snyder PhD ReMIND – Discovery Stage ReMIND Dissecting cell-specific genetic and molecular drivers of amyotrophic lateral sclerosis for therapeutic insights $12,999,837
Stanford University Sergiu P Pasca ReMIND – Discovery Stage ReMIND Transplantation of human forebrain assembloids as a platform for therapeutic screening in neurodevelopmental disorders $13,999,999
University of California, Los Angeles Daniel Geschwind ReMIND – Discovery Stage ReMIND Advancing Therapeutic Discovery Through Multimodal Analyses of Genetic and Cellular Mechanisms in Neuropsychiatric Disorders $13,957,175
University of California, San Diego Dr. Gene Wei-Ming Yeo ReMIND – Discovery Stage ReMIND Reversing age-dependent neurodegeneration by elimination of RNA pollution $11,946,234
Salk Institute for Biological Studies Christian Metallo ReMIND – Discovery Stage ReMIND Tracing the metabolic basis of neurological disorders $12,995,613
University of California, San Francisco Dr. Arnold Kriegstein ReMIND – Discovery Stage ReMIND Defining the Developmental Origins and Neuronal Regulation of Glioblastoma Stem Cells $13,578,858
University of California, San Diego Jonathan Sebat ReMIND – Discovery Stage ReMIND Modeling the genetic basis of psychopathology in schizophrenia and autism $12,703,708
University of California, San Francisco Mercedes Paredes ReMIND – Discovery Stage ReMIND Multi-gene modulation to rescue CNS-associated microdeletion syndromes $6,253,897
University of California, Los Angeles Aparna Bhaduri ReMIND – Discovery Stage ReMIND Defining Neurovascular Metabolism in Neurodevelopmental and Neuropsychiatric Disorders $10,330,000
University of California, San Francisco Tomasz Nowakowski ReMIND – Discovery Stage ReMIND CIRM Center for Neuropsychiatric Stem Cell Proteomics $13,781,522
Scripps Research Institute Xin Jin ReMIND – Discovery Stage ReMIND Translational epigenomics: dissecting cell type-specific function of neuropsychiatric risk genes in vivo $11,376,314
Scripps Research Institute Stuart A Lipton ReMIND – Discovery Stage ReMIND Multiomic Studies of Idiopathic Intellectual Disability and Autism Spectrum Disorder (ID/ASD) $17,365,387
University of California, San Francisco Alex Pollen ReMIND – Discovery Stage ReMIND Deep phenotyping of human brain organoid models of autism spectrum disorder to unravel disease heterogeneity and develop biomarkers and treatments $12,297,272
Coast to Coast Conferences & Events Calli France Conference – 2026 CIRM Trainee Network Conference CIRM Trainee Networking Conference 2026 $425,961
Coast to Coast Conferences & Events Calli France Conference – 2026 CIRM Trainee Network Conference 2025 CIRM Trainee Networking Conference $381,317
University of Southern California Dr. Francesca Mariani Conference – 2026 CIRM Trainee Network Conference Manage the 2024 CIRM Annual Trainee Network Conference $348,626
1 … 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32